PharmaRoth Labs, Inc. Announces Retail And Wholesale Distribution Channels In Mexico

LAS VEGAS, NV--(Marketwired - March 24, 2014) - PharmaRoth Labs, Inc. (OTC Pink: ROTH) (PINKSHEETS: ROTH), the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, announced today the retail and wholesale distribution channels for sales of their proprietary drug in Mexico. These distributors have come through the Company’s exclusive marketing partner, Marcas de Renombre (MDR). Sucanon® is being sold retail in Walmart, Farmacias Benavides, Farmacias del Ahorro and HEB. The wholesale distributor that supplies smaller retailers is NADRO.

MDR is also utilizing extensive media advertising for Sucanon® in Mexico to drive sales of the drug. Mexican networks TV Azteca and Televisa are broadcasting 20 and 60 seconds ads on their national channels several times per day. The advertising was created by MDR in conjunction with PharmaRoth, and was approved by the Mexican Health Authority. In conjunction with the television advertising, MDR has successfully placed product banners in Mexico City’s largest soccer stadium, making Sucanon® visible to thousands of fans, both live and during on-air television coverage of events.

“We are very excited to announce the retail and wholesale distributors that our exclusive partner, MDR, has placed our product in,” commented Luis Lopez, CEO of PharmaRoth. “The combination of placing Sucanon® in major Mexican sales outlets and the extensive advertising on the national networks have generated enormous attention for the product. The direct link between our relationship MDR and the increase in sales demonstrates the value of having the right partner in our target market,” Mr. Lopez went on to say.

For further information regarding Sucanon®, please visit PharmaRoth Labs, Inc. website at www.pharmaroth.com

About PharmaRoth

PharmaRoth Labs, Inc. (OTC Pink: ROTH) (PINKSHEETS: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth’s strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

For further information regarding Sucanon®, please visit PharmaRoth Labs, Inc. website at www.pharmaroth.com

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.